Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for Intellia Therapeutics (NTLA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Intellia Therapeutics (NTLA) stock based on the movements in the options market lately.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals

Zacks Equity Research

Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data

by Zacks Equity Research

Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.

Zacks Equity Research

3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data

by Zacks Equity Research

Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.

Zacks Equity Research

Company News for Jun 29, 2021

by Zacks Equity Research

Companies in the news are: NTLA, AVXL, MNKD, KYMR

Zacks Equity Research

Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study

by Zacks Equity Research

Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.

Zacks Equity Research

CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -4.55% and -23.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership

by Zacks Equity Research

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.